ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
David A. DeBoer
Michael D. Crittenden
Richard E. Clark
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitchell, M. E.
Right arrow Articles by Clark, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchell, M. E.
Right arrow Articles by Clark, R. E.

Ann Thorac Surg 1992;54:712-716
© 1992 The Society of Thoracic Surgeons

Articles

Nicardipine: Myocardial protection in isolated working hearts

Marc E. Mitchell, MD, David A. DeBoer, MD, Michael D. Crittenden, MD, Richard E. Clark, MD*

Surgery Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA

Accepted for publication February 18, 1992.

* Address reprint requests to Dr Clark, Cardiovascular and Pulmonary Research Center, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212.

The effectiveness of the calcium antagonist nicardipine in protecting the ischemic myocardium was evaluated using the hemodynamic recovery of isolated working rat hearts subjected to hyperkalemic cardiac arrest followed by ischemia at 37.5 °C and 10 °C. Rat hearts (n = 51) received 20 mL of cardioplegia and were subjected to 27 minutes of ischemia at 37.5 °C. Group A (control) did not receive nicardipine. Groups B through F received nicardipine in the cardioplegia with total doses ranging from 2 µg to 6 µg. Group A had 46% survival of ischemia, whereas groups C (3 µg) and D (4 µg) had survival rates of 88% and 100%, respectively (p < 0.05). The recovery of aortic flow after ischemia was 35% in group A, compared with 76% in group B (2 µg) and 81% in group D (p < 0.05). Group A had 49% postischemic recovery of cardiac output, whereas groups B and D had 82% and 85% recovery (p < 0.05). The postischemic recovery of stroke volume was 48% in group A compared with 84% in group B, 87% in group D, and 73% in group E (5 µg) (p < 0.05). Additional rats were exposed to 210 minutes of ischemia (n = 41) or 240 minutes of ischemia (n = 56) at 10 °C. Control groups did not receive nicardipine, whereas treatment groups received nicardipine in the cardioplegia with total doses ranging from 1.4 µg to 6.4 µg. There were no significant differences in the survival of ischemia or the recovery of function after ischemia at 10 °C. We conclude that nicardipine offers significant protection to the ischemic rat myocardium at normothermia, with an optimal dose of 2 to 4 µg. We have been unable to demonstrate any beneficial effect from the administration of nicardipine at 10 °C.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1992 by The Society of Thoracic Surgeons.